We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Regeneron to Buy Out Sanofi’s Stake in Jointly Developed Libtayo
Regeneron to Buy Out Sanofi’s Stake in Jointly Developed Libtayo
Regeneron Pharmaceuticals announced that it will acquire Sanofi’s stake in the Regeneron- Sanofi collaboration on the cancer drug Libtayo (cemiplimab) for $900 million up front, 11 percent royalties on worldwide sales and other milestone payments.